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Abstract 
 
OBJECTIVE: The objective of this selective EBM review is to determine whether or not 
Finasteride is effective in reducing/reversing the symptoms of androgenic alopecia. 
 
STUDY DESIGN: Reviewed three English primary studies published in 2006, 2008, and 2009. 
 
DATA SOURCES: All Studies were randomized controlled trials comparing Finasteride to 
placebo or other hair loss treatments were found using PubMED, EBSCO, MEDLINE, and 
Cochrane research databases. 
 
OUTCOME MEASURED: Overall reduction in size of balding area based on measurements of 
total hair counts. Measurements were based on macrographical analysis of test subjects’ balding 
area, as well as global photographical analysis carried out by the investigators of each trial study. 
Test subjects were given self assessment questionnaires to gather subjective views of the 
treatment. 
 
RESULTS: All three randomized controlled trials included in this review indicated that oral 
Finasteride therapy of 1-5mg demonstrated measurable reversal of hair loss in men suffering 
androgenic alopecia. 
 
CONCLUSION: Based on the three RCT’s reviewed in this study, there is measurable evidence 
to indicate the use of Finasteride in the reduction and reversal of androgenic alopecia. This 
review only analyzed the effect of Finasteride on test subjects before and after treatment. Further 
tests would need to be done to determine if Finasteride is a medication that must be taken daily 
as preventative therapy, or if it can be discontinued once hair regrowth is obtained. 
 
KEY WORDS: Finasteride; androgenic alopecia; hair loss; male pattern hair loss. 
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INTRODUCTION 
 The value that society places on hair is high, which can have a significant effect on 
quality of life and psychosocial impairment when an individual develops alopecia. Androgenic 
alopecia—also known as male pattern baldness (MPB)—is a disorder whereby there is a 
progressive shrinking of the hair follicles resulting in visible loss of hair on the scalp. MPB has 
been found to be genetically linked predisposing 50% of males by the age of 40 to the disorder; 
with white males being affected most commonly. Little is known about the true cost an 
individual will spend annually on medications or hair products to halt the recession/loss of hair; 
or, the number of annual healthcare visit seen in regards to hair loss. This may possibly be due to 
embarrassment felt by the individual over losing hair, attempts to self treat with over the counter 
remedies, or the fact that most insurance companies will not pay due to MPB being classified as 
a cosmetic condition.  
 Fortunately research has identified the causative process behind androgenic alopecia. The 
process is as a result of increased levels of 5-alpha-reductase enzymes, which convert 
testosterone into its active form of dihydrotestosterone (DHT). DHT is what is responsible for 
the symptoms of androgenic alopecia: shrinking follicles, thinking hair, and receding hair line. 
MPB has been shown to be absent in patients deficient in 5-alpha-reductase enzyme identifying 
DHT as a major factor in the disorder. Using this information, pharmacotherapy has been 
initiated as a first line treatment for individuals suffering from androgenic alopecia. Topical and 
oral forms of Minoxidil or Finasteride have been the standard medications for treatment of 
androgenic alopecia. Surgical hair grafts are also available, but are considered a last line of 
treatment. 
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 While the treatments above have been initiated as suitable medications to counteract 
MPB, no pharmacologic therapy has been shown to completely cure the results of MPB. Surgical 
intervention as listed above is an effective way, but costly treatment approach not easily 
accessible for everyone suffering from this disorder. Additionally, it does not affect the primary 
issue of increased levels of DHT. While further studies are done to find a more effective 
treatment to androgenic alopecia, this study will focus on one of the current medications—such 
as Finasteride—and assess its efficacy in reducing or reversing the effects seen in MPB. 
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not Finasteride is 
effective in reducing/reversing the symptoms of androgenic alopecia. Finasteride has been tested 
in many randomized controlled trials (RCT) indicating positive effect on hair growth and 
reduction in hair loss in men suffering from androgenic alopecia. 
METHODS 
 The studies reviewed in this article used test subjects between the ages of 18 and 45 
testing oral Finasteride therapy to either a placebo or other hair loss medications. One study 
compared 1mg Finasteride to placebo taken daily for one year. Another study compared 5mg 
Finasteride to varying potencies of Dutasteride as well as a placebo taken daily for 24 weeks. 
The third study compared oral1mg Finasteride taken daily to topical 1% finasteride gel applied 
twice a day over 6 months. At the end of each study, the results were analyzed using overall 
reduction in size of balding area based on measurements of total hair counts using 
macrophotographical analysis. All three studies reviewed in this article were randomized 
controlled trials. 
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The three randomized controlled trials reviewed in this article were found using PubMed, 
EBSCO, MEDLINE, and Cochrane research engines entering in key words such as Finasteride, 
androgenic alopecia, hair loss, and male pattern hair loss. Articles used were selected based on 
their relevance to the question posed, as well as having contained outcomes in the form of patient 
oriented evidence that mattered (POEM)  relevant to patients suffering from androgenic alopecia 
All articles were presented in English, and published in peer-reviewed journals from 2006 to 
2009. These articles met inclusion criteria if they were published after 1996, were RCT’s, and 
contained POEM’s. Articles excluded from review in this article were systematic reviews and 
articles discussed in systematic reviews that posed the same question this article aims to 
investigate. To obtain significance in the outcome of the study, dichotomous data collected from 
each article was interpreted using p-value and numbers needed to treat (NNT). 
Table 1: Demographics and Characteristics of Reviewed Studies 
Study Type Number 
of 
Patients 
Age Inclusion Criteria Exclusion 
Criteria 
W/D Interventions 
Hajheydari, 
2009 
RCT 45 <30 Males under age 
30; hair loss 
duration <5 years; 
max hair density 20 
hairs/cm2; max 
diameter of bald 
area <10cm; 
complete physical 
and psychological 
health. 
Male alopecia 
previously under 
treated; patients 
with baseline 
disease causing 
hair loss. 
7 Randomized into 
two groups to 
receive either 
topical finasteride 
(1%)+ placebo 
pill, or  topical 
placebo +  
finasteride pill 
(1mg). 
Kaufman, 
2008 
RCT 1553 18-
41 
Hamilton-Norwood 
Stages II-V. 
Norwood/Hamilt
on Classification 
Stage I. 
813 Randomized into 
two groups to 
receive either 
1mg finasteride 
orally or a 
placebo. 
Olsen, 2006 RCT 416 21-
45 
Hamilton-Norwood 
stages III-V. 
Hamilton-
Norwood stage I 
and II; use of a 5 
alpha-reductase 
inhibitor; any 
medication for 
alopecia within 6 
42 Randomized into 
6 groups to 
receive either 
dutasteride (.05, 
.1, .5, or 2.5 mg) 
finasteride (5mg), 
or a placebo. 
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months of study; 
significant health 
problems; 
androgen/anti-
androgen drug 
use within 6 
months. 
 
Outcomes measured 
 The outcomes measured from these studies were in the form of POEM’s and evaluated by 
both investigators and test subjects. The investigators of each study utilized macrographical and 
photographical analysis of test subjects’ balding areas to assess total hair counts. This method 
allowed for an enhanced view of the patient’s scalp making it easy to count individual hairs, and 
note any increases in total hair counts from pretreatment analyses. Test subjects in each study 
were given patient self assessment questionnaires to analyze if they noticed any change after the 
given treatment.  
Results 
 All three articles were presented as RCT’s. Hajheydari et al conducted a double blind 
RCT comparing topical 1% Finasteride gel to 1mg finasteride oral tablet. There were 45 subjects 
suffering from androgenic alopecia enrolled into this study that were selected from private 
clinics and the dermatology department of the City of Sari in Iran. Seven were excluded due to 
incomplete or discontinuation of the entire study period. In the Study, test subjects were 
randomized into two groups and either given a placebo gel to apply twice a day along with 1mg 
Finasteride tablet taken daily; or, 1% Finasteride gel applied twice a day with a placebo tablet 
taken daily. The study was conducted over six months and subjects analyzed at the end of each 
month. Data obtained indicated a relatively similar therapeutic response of between the two test 
groups with a moderate response of 54.5% increase in hair counts in the Finasteride gel group 
and a 56% increase in hair counts in the Finasteride Tablet group. This yielded a p-value of .643, 
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which indicates no significance or superiority over administering Finasteride topically versus 
orally; however, in regards to this article, it does prove a general therapeutic benefit of 
administration of Finasteride for treatment of androgenic alopecia, which can also be seen after 
evaluation of the data collected in Table 2. 
Table 2: Mean Hair Count and Number of Terminal Hairs before and After Therapy 
  Before Therapy After Therapy P-Value in  Each Group 
P-value Between 
Groups 
Hair Counts Gel 139.74 + 34.21 147.8 0+ 33.91 0.000 0.642 Tablet 137.89 + 35.33 153.56 + 36.28 0.000 
Number of 
Terminal Hairs 
Gel 108.42 + 37.60 113.27 + 39.74 0.001 0.661 Tablet 105.58 + 39.33 118.61 + 37.49 0.000 
*(Hajheydari et al, “Comparing Therapeutic Effects of Finasteride”)  
 
 Kaufman et al conducted a multicenter RCT in which 1553 men were selected using the 
Norwood/Hamilton Classification Scale—which classifies severity of MPB from I to V—were 
enrolled for a one year trial, which continued for four consecutive years. Test subjects were 
randomized into one of two groups: 1mg Finasteride or placebo daily for one year. During the 
subsequent four year extension studies, patients were re-randomized into experiment and control 
groups, leaving only 713 test subjects that maintained the same therapy from the start of the 
study till the end (645 on Finasteride and 68 on placebo). This article will only analyze the data 
from the 713 test subjects. The data collected from this study evaluated data collected in the form 
of  incidence rates and percent decrease in likelihood of developing further visible hair loss 
assessed by global photographic assessment expressed in events per patient-years. The study 
concluded that out of 100 patient-years 26 events of further hair loss would occur in the placebo 
group versus 3.1 in the Finasteride group. Photographical assessment of the Finasteride group 
yielded a 93% decrease in continued hair loss with an 89 to 96% confidence interval and p-value 
of .001. What this is indicating is that there is clinical significant in treating androgenic alopecia 
with Finasteride. 
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Table 3: Incidence rate and percent decrease in likelihood of developing further hair  
   loss. 
Placebo Finasteride Percent Decrease in likelihood 
with Finasteride 1mg relative to 
Placebo (95% CI) 
N (%) Incidence Rate  
(Event/100 Patient-years) 
N (%) Incidence Rate 
 (Event/100 Patient-years) 
68 (100) 26.0 645 (100) 3.1 93% (89,96) 
*(Kauffman et al, “Long-term Treatment with Finasteride”) 
  In Olsen et al enrolled 416 men into a RCT study who were suffering from mild to 
moderate MPB using the Norwood-Hamilton classification III to V. The study aimed to compare 
Finasteride 5 mg to placebo and Dutasteride 0.05, 0.1, 0.5, and 2.5 mg carried out over 24 weeks. 
For this article review, we will only focus on the Finasteride treatment as it compares to the 
placebo. Efficacy was determined by hair counts measured using macrophotographical evidence. 
Data in this study was in the form of continuous data. Data was converted into dichotomous form 
to fit the results of the previous studies. At the end of the 24 weeks, there were 68 participants 
still left in the Finasteride group, and 50 in the controlled placebo group. In comparison, 41% of 
test subjects in the Finasteride group saw at least a 10% increase in hair counts compared to 0% 
in the control group.  
Table 4 analyzes the data collected from each study in an attempt to confirm the efficacy 
of experimental Finasteride to the control group. In Kaufman et al and Olsen et al studies 
comparing Finasteride to a placebo, one sees the significance of administration of Finasteride for 
treatment of androgenic alopecia in the low NNT. What this number is identifying is that in order 
to see a reduction of reversal of MPB in one person, you would need to treat 4 or 3 people 
respectively suffering from MPB with Finasteride, which again is clinically significant. In 
Hajheydari et al study comparing topical to oral Finasteride therapy, you see a high NNT, which 
indicates no real significance of administering oral Finasteride over topical. However, as we 
stated above and presented in Table 2, there is clinical evidence that identified an increase in hair 
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counts after administration of oral Finasteride, which further proves clinical significance of using 
Finasteride for reduction of androgenic alopecia. 
Table 4: Analysis of Data From Each Study in Relevance to RBI/ABI/ NNT 
 Controlled Event 
Rate 
(CER) 
Experimental 
Event Rate (EER) 
Relative Benefit 
Increase 
 (RBI) 
Absolute Benefit 
Increase  
(ABI) 
Numbers Needed 
to Treat  
(NNT) 
Hajheydari  
et al 54.5% 5% 0.0275 0.015 67 
Kaufman et al 74% 96.9% 0.309 0.229 4 
Olsen et al 0% 41% 0 .41 3 
 
Each study in this article comments on adverse events experienced during the Study. 
Hajheydari et al recorded one complaint of erythema with topical Finasteride, and one complaint 
of decreased libido with oral Finasteride. Kaufman et al recorded 1.8%, 1.3%, and 1.2% of test 
subjects who experienced decreased libido, erectile dysfunction, and ejaculation disorder 
respectively.  Olsen et al recorded 11 subjects who experienced adverse events; however, 
adverse events were not explained in this study. Only Olsen et al documented compliance, 
measured by pill counts, which was between 94% and 99%. 
Discussion 
 Across all three studies analyzed in this article, there has been positive evidence to agree 
that Finasteride therapy is beneficial in slowing or reversing MPB. All three studies noted 
increased hair counts by the sixth month, including the five year study conducted by Olsen et al.  
Kaufman et al noted a need for larger sample sizes and longer assessment periods, but aside from 
her notes, there appeared to be no other limitations that were identified, nor that the studies 
noted.  All participants were double blinded and randomized for the trials. 
 Finasteride can be a simple routine therapy for the treatment of androgenic alopecia. 
Finasteride pills are easily tolerated, only interacting with one other drug—nevirapine—which 
may increase speed of clearance from the body. Contraindications to medication use are seen in 
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pregnant or lactating women due to known teratogenicity, and individuals with hepatic 
impairment or hypersensitivity. Adverse effects, as stated prior, such as decreased libido, 
ejaculate volume decrease, and erectile dysfunction have been seen. Sold under the brand name 
Propecia, this hair loss medication requires a prescription from your physician. Unfortunately, 
MPB is seen as a cosmetic disorder, which results in essentially no coverage or defrayment of 
cost by most health insurances. Out of pocket expense for Finasteride averages $184.99 for a 90 
day supply (roughly $2.06 per pill). This would not be a poor investment if alopecia was halted 
or reversed permanently; however, if the medication is discontinued, hair loss will resume within 
12 months.  Even though surgical interventions such as hair grafts may be more costly, it may be 
a better long term alternative to taking Finasteride pills daily for life as the results of hair grafts 
are permanent. 
Conclusion 
 After a review of the three studies in this article, we can confirm that there is efficacy 
behind the administration of Finasteride for the treatment of androgenic alopecia. All studies 
appeared to have taken appropriate precautions to prevent any flaws or bias in the experiments. 
Duration of studies may have been an issue with two of the studies lasting only six months; 
however, the Kaufman et al study was carried out for one year, with a four year extension 
covering long term therapy and efficacy of treatment. Given that this article aimed to evaluate 
the efficacy of only Finasteride, future studies should aim to compare other medications utilized 
to treat androgenic alopecia—as is seen in the Olsen et al study. 
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